This is good news, even though the timeline is not that good -- 2 years for this Phase(?):
Estimated Enrollment: 16
Study Start Date: January 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Let's hope that this will not delay the entry of the PPMO in trials.
PORTLAND, OR — February 19, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced treatment of the first patient in a clinical trial evaluating the systemic delivery of AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD).
“We are very pleased to begin the systemic evaluation of our exon skipping drug — AVI-4658 — for the treatment of DMD,” said Stephen Shrewsbury, M.D., Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs of AVI BioPharma. “We believe that this trial will build significantly on the data generated by the successful recent trial evaluating intramuscular administration of the same drug in DMD boys.” ...